[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Navigation Landing]
July 1, 2009

Biomarkers and Cardiovascular Disease: Determining Causality and Quantifying Contribution to Risk Assessment

Author Affiliations

Author Affiliations: Division of Cardiology, Department of Medicine, and Center for Human Genetics, Duke University Medical Center, Durham, North Carolina (Dr Shah); and Department of Medicine, Division of Cardiology, University of Texas Southwestern Medical Center, Dallas (Dr de Lemos).

JAMA. 2009;302(1):92-93. doi:10.1001/jama.2009.949

Personalized medicine aims to use individual biological signals to improve disease detection, risk stratification, and therapeutic selection. Such a strategy holds great appeal to practitioners, who are increasingly disillusioned with the “one size fits all” approach that characterizes contemporary medicine. Key to achieving these goals is integration of genetics and biomarkers with currently available clinical data. While the model of personalized medicine is appealing, many questions remain about which markers are diagnostic, prognostic, or pathologic.